Status:
COMPLETED
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JP
Lead Sponsor:
Chugai Pharmaceutical
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
20-75 years
Phase:
PHASE3
Brief Summary
This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA220JP or MRA221JP.
Eligibility Criteria
Inclusion
- Inclusion criteria
- RA patients who participated in the previous studies
- Patients who completed the last observation in the previous studies
- Patients who were confirmed to have no problems with safety in the previous studies.
- Exclusion criteria
- Patients with Class IV Steinbrocker functional disorder at evaluation within 4 weeks before treatment with the investigational product
- Patients who were not enrolled by 3 months after the last observation day of the previous study
Exclusion
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00144586
Start Date
March 1 2005
End Date
June 1 2009
Last Update
August 9 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.